A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs2016 · 742 citations
2. 2Pancreatic Cancer2000 · 7,246 citations
3. 3Reporting Recommendations for Tumor Marker Prognostic Studies2005 · 775 citations
4. 4Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial2017 · 34 citations
5. 5Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer2013 · 1,802 citations